Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

A Phase I Study of CX5461

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: CX5461

First Posted Date: 2016-03-25

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 41

Registration Number: NCT02719977

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

Does Anxiety in Children on the Day of Surgery Impact Compliance in the Ophthalmology Clinic?

Conditions: Anxiety
Strabismus
Compliance

First Posted Date: 2016-03-10

Last Posted Date: 2018-04-26

Lead Sponsor: Queen's University

Target Recruit Count: 82

Registration Number: NCT02704442

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania

Not Applicable

Completed

Conditions: Cervical Cancer

Interventions: Behavioral: Motivational SMS
Behavioral: Travel Voucher

First Posted Date: 2016-02-11

Last Posted Date: 2018-01-29

Lead Sponsor: Queen's University

Target Recruit Count: 851

Registration Number: NCT02680613

Locations: 🇹🇿
Pamoja Tunaweza Women's Center, Moshi, Kilimanjaro, Tanzania

Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Durvalumab
Drug: Trastuzumab

First Posted Date: 2016-01-07

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 15

Registration Number: NCT02649686

Locations: 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

Same Day Bidirectional Endoscopies - Does the Sequence of Procedures or Choice of Insufflator Matter?

Not Applicable

Completed

Conditions: Colon Polyps
Anemia

Interventions: Device: Carbon dioxide insufflation
Device: room air insufflation
Procedure: EGD (Esophagogastroduodenoscopy) before Colonoscopy
Procedure: Colonoscopy before EGD (Esophagogastroduodenoscopy)

First Posted Date: 2015-12-18

Last Posted Date: 2018-05-09

Lead Sponsor: Queen's University

Target Recruit Count: 200

Registration Number: NCT02635217

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Palbociclib 125mg
Drug: Palbociclib 100mg
Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor

First Posted Date: 2015-12-15

Last Posted Date: 2023-12-20

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 180

Registration Number: NCT02630693

Locations: 🇨🇦
Royal Victoria Regional Health Centre, Barrie, Ontario, Canada
🇨🇦
CHA-Hopital Du St-Sacrement, Quebec City, Quebec, Canada
🇨🇦
BCCA - Abbotsford Centre, Abbotsford, British Columbia, Canada

and more 19 locations

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: AZD2014

First Posted Date: 2015-12-02

Last Posted Date: 2023-08-04

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 15

Registration Number: NCT02619864

Locations: 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦
QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada

and more 1 locations

The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing

Not Applicable

Completed

Conditions: Colonoscopy Preparation Outcome

Interventions: Drug: Sennosides

First Posted Date: 2015-12-01

Last Posted Date: 2018-05-09

Lead Sponsor: Queen's University

Target Recruit Count: 100

Registration Number: NCT02618564

Locations: 🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2015-11-04

Last Posted Date: 2023-08-28

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 76

Registration Number: NCT02597062

Locations: 🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
University Health Network, Toronto, Ontario, Canada

and more 6 locations

Magnesium Sulfate in Adductor Canal Blocks

Phase 4

Completed

Conditions: Knee Arthroplasty

Interventions: Other: Sham
Drug: Magnesium Sulfate
Drug: Ropivacaine

First Posted Date: 2015-10-21

Last Posted Date: 2020-11-13

Lead Sponsor: Queen's University

Target Recruit Count: 130

Registration Number: NCT02581683

Locations: 🇨🇦
Kingston General Hospital, Kingston, Ontario, Canada
🇨🇦
Hotel Dieu Hospital, Kingston, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy